In September 2024, Terns Pharmaceuticals announced positive results from its Phase 1 clinical trial for TERN-601, a once-daily oral GLP-1 receptor agonist aimed at treating obesity
Proxy forms can be downloaded from the website of the Company, www.ascendispharma.com , and must be forwarded to Computershare A/S, Lottenborgsvej 26 D, 1st floor, DK-2800 Kgs
Common side effects include nausea, constipation, diarrhea, reflux, and decreased appetite
The linked sources lead to PubMed and open in a new tab
To qualify for a Semaglutide GLP-1 prescription specifically for weight management, individuals must first undergo a comprehensive medical assessment conducted by a healthcare provider
Do not forget to add some yogurt and salmon to your cart next time you are out shopping, your body will thank you